Overcoming Cell and Gene Therapy Manufacturing Roadblocks: How Strategic Partnerships Enable Robust Early-Stage Clinical Manufacturing
Cell and gene therapies offer the promise of transformative treatments, but they come with tremendous process development and manufacturing challenges.
When sponsors aim to expedite their journey from concept to clinical trials, they face a pivotal decision: whether to establish internal capabilities or collaborate with specialized Contract Development and Manufacturing Organizations (CDMOs) to chart a cost-efficient course forward.
This talk will explore how leveraging collaborative partnerships can help guide a rapid transition into first-in-human studies.
Attendees will gain insights into process development cases from upstream to downstream manufacturing of drug substances (plasmid DNA, AAV, LVV, mRNA) and drug products (clinical cell therapy).